The neurobiology of panic disorder: Toward an integrated model

CNS Spectrums

Volumn 10, Issue 9 SUPPL. 12, 2005, Pages 12-24

  Stein, Dan J ^a,b,c  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b UNIVERSITY OF FLORIDA   (United States)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; CAFFEINE; CARBON DIOXIDE; CHOLECYSTOKININ; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; IMIPRAMINE; LACTIC ACID; METIROSINE; NORADRENALIN; NORADRENALIN UPTAKE INHIBITOR; REBOXETINE; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; TETRAGASTRIN; TRICYCLIC ANTIDEPRESSANT AGENT; YOHIMBINE;

AGORAPHOBIA; ANTICIPATION; ANXIETY; DIAGNOSTIC IMAGING; FEAR; GENETIC ANALYSIS; HUMAN; NEUROBIOLOGY; NEUROCHEMISTRY; NEUROSCIENCE; PANIC; PRIORITY JOURNAL; PROVOCATION TEST; PSYCHIATRIC DIAGNOSIS; REVIEW; TREATMENT PLANNING;

EID: 27444438168     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/s109285290002650x     Document Type: Review

References (229)

1. Diagnostic and Statistical Manual of Mental Disorders. 4th ed text rev. Washington, DC: American Psychiatric Association; 2000.
2. 2 challenge. Am J Psychiatry. 1999;156:739-744.
3. Beck JG, Shipherd JC, Ohtake P. Do panic symptom profiles influence response to a hypoxic challenge in patients with panic disorder? A preliminary report. Psychosom Med. 2000;62:678-683.
4. Chambless DL, Beck AT, Gracely EJ, Grisham JR. Relationship of cognitions to fear of somatic symptoms: a test of the cognitive theory of panic. Depress Anxiety. 2000;11:1-9.
5. Austin DW, Richards JC. The catastrophic misinterpretation model of panic disorder. Behav Res Ther. 2001;39:1277-1291.
6. Clark DM, Salkovskis PM, Ost LG, et al. Misinterpretation of body sensations in panic disorder. J Consult Clin Psychol. 1997;65:203-213.
7. Harvey JM, Richards JC, Dziadosz T, Swindell A. Misinterpretation of ambiguous stimuli in panic disorder. Cognit Ther Res. 1993;17:235-248.
8. McNally RJ. Anxiety sensitivity and panic disorder. Biol Psychiatry. 2002;52:938-946.
9. Holt PE, Andrews G. Provocation of panic: three elements of the panic reaction in four anxiety disorders. Behav Res Ther. 1989;27:253-261.
10. Clark DM, Salkovskis PM, Hackmann A, Welb A, Ludgate J, Gelder M. Brief cognitive therapy for panic disorder: a randomized controlled trial. J Consult Clin Psychol. 1999;67:583-589.
11. Beck AT, Sokol L, Clark DA, Berchick R, Wright F. A crossover study of focused cognitive therapy for panic disorder. Am J Psychiatry. 1992;149:778-783.
12. Beck JG, Stanley MA, Baldwin LE, Deagle EA III, Averill PM. Comparison of cognitive therapy and relaxation training for panic disorder. J Consult Clin Psychol. 1994;62:818-826.
13. Barlow DH, Gorman JM, Shear MK, Woods SW. Cognitive-behavioral therapy, imipramine, or their combination for panic disorder: A randomized controlled trial. JAMA. 2000;283:2529-2536.
14. Craske MG, Maidenberg E, Bystritsky A. Brief cognitive-behavioral versus nondirective therapy for panic disorder. J Behav Ther Exp Psychiatry. 1995;26:113-120.
15. Bouton ME, Mineka S, Barlow DH. A modern learning theory perspective on the etiology of panic disorder. Psychol Rev. 2001;108:4-32.
16. Reiss S. Expectancy model of fear, anxiety, and panic. Clin Psychol Rev. 1991;11:141-153.
17. Reiss S, Peterson RA, Gursky DM, McNally RJ. Anxiety sensitivity, anxiety frequency and the predictions of fearfulness. Behav Res Ther. 1986;24:1-8.
18. Taylor S, Koch WJ, McNally RJ. How does anxiety sensitivity vary across the anxiety disorders? J Anxiety Disord. 1992;6:249-259.
19. Schmidt NB, Lerew DR, Jackson RJ. Prospective evaluation of anxiety sensitivity in the pathogenesis of panic: replication and extension. J Abnorm Psychol. 1999;108:532-537.
20. Schmidt NB, Lerew DR, Jackson RJ. The role of anxiety sensitivity in the pathogenesis of panic: prospective evaluation of spontaneous panic attacks during acute stress. J Abnorm Psychol. 1997;106:355-364.
21. Eke M, McNally RJ. Anxiety sensitivity, suffocation fear, trait anxiety, and breath-holding duration as predictors of response to carbon dioxide challenge. Behav Res Ther. 1996;34:603-607.
22. Rapee RM, Brown TA, Antony MM, Barlow DH. Response to hyperventilation and inhalation of 5.5% carbon dioxide-enriched air across the DSM-III-R anxiety disorders. J Abnorm Psychol. 1992;101:538-552.
23. Rapee RM, Medoro L. Fear of physical sensations and trait anxiety as mediators of the response to hyperventilation in nonclinical subjects. J Abnorm Psychol. 1994;103:693-699.
24. Rassovsky Y, Kushner MG, Schwarze NJ, Wangensteen OD. Psychological and physiological predictors of response to carbon dioxide challenge in individuals with panic disorder. J Abnorm Psychol. 2000;109:616-623.
25. Koszycki D, Bradwejn J. Anxiety sensitivity does not predict fearful responding to 35% carbon dioxide in patients with panic disorder. Psychiatry Res. 2001;101:137-143.
26. Koszycki D, Zacharko RM, Bradwejn J. Influence of personality on behavioral response to cholecystokinin-tetrapeptide in patients with panic disorder. Psychiatry Res. 1996;62:131-138.
27. Stein MB, Jang KL, Livesley WJ. Heritability of anxiety sensitivity: a twin study. Am J Psychiatry. 1999;156:246-251.
28. Klein DF. False suffocation alarms, spontaneous panics, and related conditions. An integrative hypothesis. Arch Gen Psychiatry. 1993;50:306-317.
29. Cowley DS, Roy-Byrne PP. Hyperventilation and panic disorder. Am J Med. 1987;83:929-937.
30. Forsyth JP, Eifert GH. Systemic alarms in fear conditioning I: a reappraisal of what is being conditioned. Behav Ther. 1996;27:441-462.
31. Davis M. Neural circuitry of anxiety and stress disorders. In: Davis KL, Charney D, Coyle JT, Nemeroff C, eds. Neuropsychopharmacology: The Fifth Generation of Progress. Philadelphia, PA: Lippincott Williams & Wilkins; 2002:931-951.
32. Clark DM. A cognitive model of panic attacks. In: Rachman S, Maser JD, eds. Panic: Psychological Perspective. Hillside, New Jersey: Erlbaum; 1988:71-89.
33. Rachman S. Neo-conditioning and the classical theory of fear acquisition. Clin Psychol Rev. 1991;11:155-173.
34. Ayuso JL, Alfonso S, Rivera A. Childhood separation anxiety and panic disorder: a comparative study. Prog Neuropsychopharmacol Biol Psychiatry. 1989;13:665-671.
35. Gittelman R, Klein DF. Relationship between separation anxiety and panic and agoraphobic disorders. Psychopathology. 1984;17(Suppl 1):56-65.
36. Tweed JL, Schoenbach VJ, George LK, Blazer DG. The effects of childhood parental death and divorce on six-month history of anxiety disorders. Br J Psychiatry. 1989;154:823-828.
37. Manfro GG, Otto MW, McArdle ET, et al. Relationship of antecedent stressful life events to childhood and family history of anxiety and the course of panic disorder. J Affect Disord. 1996;41:135-139.
38. Aschenbrand SG, Kendall PC, Webb A, Safford SM, Flannery-Schroeder E. Is childhood separation anxiety disorder a predictor of adult panic disorder and agoraphobia? A seven-year longitudinal study. J Am Acad Child Adolesc Psychiatry. 2003;42:1478-1485.
39. Van der Molen GM, van den Hout MA, van Dieren AC, Griez E. Childhood separation anxiety and adult onset panic disorders. J Anxiety Disord. 1989;3:97-106.
40. Otto MW, Pollack MH, Maki KM, et al. Childhood history of anxiety disorders among adults with social phobia: rates, correlates, and comparisons with patients with panic disorder. Depress Anxiety. 2001;14:209-213.
41. Stewart CA, Petrie RX, Balfour DJ, Matthews K, Reid IC. Enhanced evoked responses after early adversity and repeated platform exposure: the neurobiology of vulnerability? Biol Psychiatry. 2004;55:868-870.
42. Gutman DA, Nemeroff CB. Neurobiology of early life stress: rodent studies. Semin Clin Neuropsychiatry. 2002;7:89-95.
43. Charney DS. Neuroanatomical circuits modulating fear and anxiety behaviors. Acta Psychiatr Scand Suppl. 2003;38-50.
44. Gutman DA, Nemeroff CB. Persistent central nervous system effects of an adverse early environment: clinical and preclinical studies. Physiol Behav. 2003;79:471-478.
45. Goodwin RD, Eaton WW. Asthma and the risk of panic attacks among adults in the community. Psychol Med. 2003;33:879-885.
46. Hasler G, Gergen PJ, Kleinbaum DG, et al. Asthma and panic in young adults: a 20-year prospective community study. Am J Respir Crit Care Med. 2005;171:1224-1230.
47. 2 levels: a test of Klein's (1993) suffocation alarm theory of panic. J Abnorm Psychol. 1996;105:446-454.
48. Gorman JM, Kent JM, Sullivan GM, Coplan JD. Neuroanatomical hypothesis of panic disorder, revised. Am J Psychiatry. 2000;157:493-505.
49. Charney DS, Drevets WC. Neurobiological basis of anxiety disorders. In: Davis KL, Charney D, Coyle JT, Nemeroff C, eds. Neuropsychopharmacology: The Fifth Generation of Progress. Philadelphia, PA: Lippincott Williams & Wilkins; 2002:901-930.
50. Bechara A, Tranel D, Damasio H, Adolphs R, Rockland C, Damasio AR. Double dissociation of conditioning and declarative knowledge relative to the amygdala and hippocampus in humans. Science. 1995;269:1115-1118.
51. Salloway S, White J. Paroxysmal limbic disorders in neuropsychiatry. J Neuropsychiatry Clin Neurosci. 1997;9:403-419.
52. Cannistraro PA, Rauch SL. Neural circuitry of anxiety: evidence from structural and functional neuroimaging studies. Psychopharmacol Bull. 2003;37:8-25.
53. Rauch SL, Shin LM. Structural and functional imaging of anxiety and stress disorders. In: Davis KL, Charney D, Coyle JT, Nemeroff C, eds. Neuropsychophamacology: The Fifth General of Progress. Nashville, Tennessee: American College of Neuropsychopharmacology; 2002:953-966.
54. Stewart RS, Devous MD, Sr., Rush AJ, Lane L, Bonte FJ. Cerebral blood flow changes during sodium-lactate-induced panic attacks. Am J Psychiatry. 1988;145:442-449.
55. Woods SW, Koster K, Krystal JK, et al. Yohimbine alters regional cerebral blood flow in panic disorder. Lancet. 1988;2:678.
56. Reiman EM, Raichle ME, Robins E, et al. Neuroanatomical correlates of a lactate-induced anxiety attack. Arch Gen Psychiatry. 1989;46:493-500.
57. Maddock RJ, Buonocore MH, Kile SJ, Garrett AS. Brain regions showing increased activation by threat-related words in panic disorder. Neuroreport. 2003;14:325-328.
58. Reiman EM, Raichle ME, Robins E, et al. The application of positron emission tomography to the study of panic disorder. Am J Psychiatry. 1986;143:469-477.
59. De Cristofaro MT, Sessarego A, Pupi A, Biondi F, Faravelli C. Brain perfusion abnormalities in drug-naive, lactate-sensitive panic patients: a SPECT study. Biol Psychiatry. 1993;33:505-512.
60. Nordahl TE, Semple WE, Gross M, et al. Cerebral glucose metabolic differences in patients with panic disorder. Neuropsychopharmacology. 1990;3:261-272.
61. Bisaga A, Katz JL, Antonini A, et al. Cerebral glucose metabolism in women with panic disorder. Am J Psyhiatry. 1998;155:1178-1183.
62. Boshuisen ML, Ter Horst GJ, Paans AM, Reinders AA, den Boer JA. rCBF differences between panic disorder patients and control subjects during anticipatory anxiety and rest. Biol Psychiatry. 2002;52:126-135.
63. Fontaine R, Breton G, Dery R, Fontaine S, Elie R. Temporal lobe abnormalities in panic disorder: an MRI study. Biol Psychiatry. 1990;27:304-310.
64. Vythilingam M, Anderson ER, Goddard A, et al. Temporal lobe volume in panic disorder-a quantitative magnetic resonance imaging study. Psychiatry Res. 2000;99:75-82.
65. Massana G, Serra-Grabulosa JM, Salgado-Pineda P, et al. Parahippocampal gray matter density in panic disorder: a voxel-based morphometric study. Am J Psychiatry. 2003;160:566-568.
66. Massana G, Serra-Grabulosa JM, Salgado-Pineda P, et al. Amygdalar atrophy in panic disorder patients detected by volumetric magnetic resonance imaging. Neuroimage. 2003;19:80-90.
67. Redmond DE, Jr., Huang YH. Current concepts. II. New evidence for a locus coeruleus-norepinephrine connection with anxiety. Life Sci. 1979;25:2149-2162.
68. Coplan JD, Lydiard RB. Brain circuits in panic disorder. Biol Psychiatry. 1998;44:1264-1276.
69. Johnson MR, Lydiard RB, Ballenger JC. Panic disorder. Pathophysiology and drug treatment. Drugs. 1995;49:328-344.
70. Charney DS, Heninger GR, Breier A. Noradrenergic function in panic anxiety. Effects of yohimbine in healthy subjects and patients with agoraphobia and panic disorder. Arch Gen Psychiatry. 1984;41:751-763.
71. Nesse RM, Cameron OG, Curtis GC, McCann DS, Huber-Smith MJ. Adrenergic function in patients with panic anxiety. Arch Gen Psychiatry. 1984;41:771-776.
72. Pohl R, Yetagani VK, Balon R, et al. Isoproterenol-induced panic attacks. Biol Psychiatry. 1988;24:891-902.
73. Brambilla F, Perna G, Garberi A, Nobile P, Bellodi L. Alpha 2-adrenergic receptor sensitivity in panic disorder: I. GH response to GHRH and clonidine stimulation in panic disorder. Psychoneuroendocrinology. 1995;20:1-9.
74. Charney DS, Woods SW, Krystal JH, Nagy LM, Heninger GR. Noradrenergic neuronal dysregulation in panic disorder: the effects of intravenous yohimbine and clonidine in panic disorder patients. Acta Psychiatr Scand. 1992;86:273-282.
75. Yeragani VK, Tancer M, Uhde T. Heart rate and QT interval variability: abnormal alpha-2 adrenergic function in patients with panic disorder. Psychiatry Res. 2003;121:185-196.
76. Abelson JL, Glitz D, Cameron OG, Lee MA, Bronzo M, Curtis GC. Endocrine, cardiovascular, and behavioral responses to clonidine in patients with panic disorder. Biol Psychiatry. 1992;32:18-25.
77. Schittecatte M, Charles G, Depauw Y, Mesters P, Wilmotte J. Growth hormone response to clonidine in panic disorder patients. Psychiatry Res. 1988;23:147-151.
78. Schittecatte M, Ansseau M, Charles G, et al. Growth hormone response to clonidine in male patients with panic disorder untreated by antidepressants. Psychol Med. 1992;22:1059-1062.
79. Uhde TW, Stein MB, Vittone BJ, et al. Behavioral and physiologic effects of short-term and long-term administration of clonidine in panic disorder. Arch Gen Psychiatry. 1989;46:170-177.
80. Bakker A, van Balkom AJ, Stein DJ. Evidence-based pharmacotherapy of panic disorder. Int J Neuropsychopharmacol. 2005;8:473-482.
81. Versiani M, Cassano G, Perugi G, et al. Reboxetine, a selective norepinephrine reuptake inhibitor, is an effective and well-tolerated treatment for panic disorder. J Clin Psychiatry. 2002;63:31-37.
82. Dannon PN, Iancu I, Grunhaus L. The efficacy of reboxetine in the treatment-refractory patients with panic disorder: an open label study. Hum Psychopharmacol. 2002;17:329-333.
83. Seedat S, van Rheede vO, Muller JE, Mohr N, Stein DJ. Reboxetine and citalopram in panic disorder: a single-blind, cross-over, flexible-dose pilot study. Int Clin Psychopharmacol. 2003;18:279-284.
84. Bertani A, Perna G, Migliarese G, et al. Comparison of the treatment with paroxetine and reboxetine in panic disorder: a randomized, single-blind study. Pharmacopsychiatry. 2004;37:206-210.
85. Drug treatment of panic disorder. Comparative efficacy of alprazolam, imipramine, and placebo. Cross-National Collaborative Panic Study, Second Phase Investigators. Br Psychiatry. 1992;160:191-202.
86. den Boer JA. Pharmacotherapy of panic disorder: differential efficacy from a clinical viewpoint. J Clin Psychiatry. 1998;59(Suppl 8):30-36.
87. Mavissakalian M, Perel JM. Protective effects of impramine maintenance treatment in panic disorder with agoraphobia. Am J Psychiatry. 1992;149:1053-1057.
88. Ballenger JC, Wheadon DE, Steiner M, Bushnell W, Gergel IP. Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder. Am J Psychiatry. 1998;155:36-42.
89. Bandelow B, Behnke K, Lenoir S, et al. Sertraline versus paroxetine in the treatment of panic disorder: an acute, double-blind noninferiority comparison. J Clin Psychiatry. 2004;65:405-413.
90. Lecrubier Y, Judge R. Long-term evaluation of paroxetine, clomipramine and placebo in panic disorder. Collaborative Paroxetine Panic Study Investigators. Acta Psychiatr Scand. 1997;95:153-160.
91. Perna G, Bertani A, Caldirola D, Smeraldi E, Bellodi L. A comparison of citalopram and paroxetine in the treatment of panic disorder: a randomized, single-blind study. Pharmacopsychiatry. 2001;34:85-90.
92. Modigh K, Westberg P, Eriksson E. Superiority of clomipramine over imipramine in the treatment of panic disorder: a placebo-controlled trial. J Clin Psychopharmacol. 1992;12:251-261.
93. Mavissakalian MR. Imiprmaine vs. sertraline in panic disorder: 24-week treatment completers. Ann Clin Psychiatry. 2003;15:171-180.
94. Bakker A, van Balkom AJ, Spinhoven P. SSRIs vs. TCAs in the treatment of panic disorder: a meta-analysis. Acta Psychiatr Scand. 2002;106:163-167.
95. Otto MW, Tuby KS, Gould RA, McLean RY, Pollack MH. An effect-size analysis of the relative efficacy and tolerability of serotonin selective reuptake inhibitors for panic disorder. Am J Psychiatry. 2001;158:1989-1992.
96. Coplan JD, Gorman JM, Klein DF. Serotonin related functions in panic-anxiety: a critical overview. Neuropsychopharmacology. 1992;6:189-200.
97. Handley SL. 5-Hydroxytryptamine pathways in anxiety and its treatment. Pharmacol Ther. 1995;66:103-148.
98. Harvey BH, Naciti C, Brand L, Stein DJ. Serotonin and stress: protective or malevolent actions in the biobehavioral response to repeated trauma? Ann N Y Acad Sci. 2004;1032:267-272.
99. Evans L, Schneider P, Ross-Lee L, et al. Plasma serotonin levels in agoraphobia. Am J Psychiatry. 1985;142:267.
100. Schneider P, Evans L, Ross-Lee L, et al. Plasma biogenic amine levels in agoraphobia with panic attacks. Pharmacopsychiatry. 1987;20:102-104.
101. Norman TR, Judd FK, Burrows GD, McIntyre IM. Platelet serotonin uptake in panic disorder patients: a replication study. Psychiatry Res. 1989;30:63-68.
102. Norman TR, Judd FK, Gregory M, et al. Platelet serotonin uptake in panic disorder. J Affect Disord. 1986;11:69-72.
103. McIntyre IM, Judd FK, Burrows GD, Norman TR. Serotonin in panic disorder: platelet uptake and concentration. Int Clin Psychopharmacol. 1989;4:1-6.
104. Balon R, Pohl R, Yeragani V, Rainey J, Oxenkrug GF. Platelet serotonin levels in panic disorder. Acta Psychiatr Scand. 1987;75:315-317.
105. Eriksson E, Westberg P, Alling C, Thuresson K, Modigh K. Cerebrospinal fluid levels of monoamine metabolites in panic disorder. Psychiatry Res. 1991;36:243-251.
106. Lesch KP, Wiesmann M, Hoh A, et al. 5-HT1A receptor-effector system responsivity in panic disorder. Psychopharmacology (Berl). 1992;106:111-117.
107. Meyer JH, Swinson R, Kennedy SH, Houle S, Brown GM. Increased left posterior parietal-temporal cortex activation after D-fenfluramine in women with panic disorder. Psychiatry Res. 2000;98:133-143.
108. Targum SD, Marshall LE. Fenfluramine provocation of anxiety in patients with panic disorder. Psychiatry Res. 1989;28:295-306.
109. Bell C, Forshall S, Adrover M, et al. Does 5-HT restrain panic? A tryptophan depletion study in panic disorder patients recovered on paroxetine. J Psychopharmacol. 2002;16:5-14.
110. Maron E, Kuikka JT, Shlik J, Vasar V, Vanninen E, Tiihonen J. Reduced brain serotonin transporter binding in patients with panic disorder. Psychiatry Res. 2004;132:173-181.
111. Neumeister A, Bain E, Nugent AC, et al. Reduced serotonin type 1A receptor binding in panic disorder. J Neurosci. 2004;24:589-591.
112. Bakker A, van Dyck R, Spinhoven P, van Balkom AJ. Paroxetine, clomipramine, and cognitive therapy in the treatment of panic disorder. J Clin Psychiatry. 1999;60:831-838.
113. Londborg PD, Wolkow R, Smith WT, et al. Sertraline in the treatment of panic disorder. A multi-site, double-blind, placebo-controlled, fixed-dose investigation. Br J Psychiatry. 1998;173:54-60.
114. Pohl RB, Wolkow RM, Clary CM. Sertraline in the treatment of panic disorder: a double-blind multicenter trial. Am J Psychiatry. 1998;155:1189-1195.
115. Pollack MH, Otto MW, Worthington JJ, Manfro GG, Wolkow R. Sertraline in the treatment of panic disorder: a flexible-dose multicenter trial. Arch Gen Psychiatry. 1998;55:1010-1016.
116. Rapaport MH, Wolkow R, Rubin A, Hackett E, Pollack M, Ota KY. Sertraline treatment of panic disorder: results of a long-term study. Acta Psychiatr Scand. 2001;104:289-298.
117. Leinonen E, Lepola U, Koponen H, Turtonen J, Wade A, Lehto H. Citalopram controls phobic symptoms in patients with panic disorder: randomized controlled trial. J Psychiatry Neurosci. 2000;25:25-32.
118. Lepola UM, Wade AG, Leinonen EV, et al. A controlled, prospective, 1-year trial of citaloptam in the treatment of panic disorder. J Clin Psychiatry. 1998;59:528-534.
119. Stahl SM, Gergel I, Li D. Escitalopram in the treatment of panic disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2003;64:1322-1327.
120. Ballenger JC, Davidson JR, Lecrubier Y, et al. Consensus statement on panic disorder from the International Consensus Group on Depression and Anxiety. J Clin Psychiatry. 1998;59:47-54.
121. Pollack MH, Allgulander C, Bandelow B, et al. WCA recommendations for the long-term treatment of panic disorder. CNS Spectr. 2003;8:17-30.
122. Geracioti TD, Jr. Venlafaxine treatment of panic disorder: a case series. J Clin Psychiatry. 1995;56:408-410.
123. Liebowitz MR., Asnis G, Tzanis E, Whitaker T. A placebo-controlled trial of venlafaxine XR in the short-term treatment of panic disorder. Poster presented at: Annual Meeting of the Collegium Internationale Neuropsychopharmacolog icum; June 20-24, 2004; Paris, France
124. Papp LA, Sinha SS, Martinez JM, Coplan JD, Amchin J, German JM. Low-dose venlafaxine treatment in panic disorder. Psychopharmacol Bull. 1998;34:207-209.
125. Pollack M, Emilien G, Tzanis E, Whitaker T. Venlafaxine XR and paroxetine in the short-term treatment of panic disorder. Presented at: Annual Meeting of the World Federation for the Societies of Biological Psychiatry: February 9-13, 2004; Sydney, Australia
126. Pollack M, Whitaker T, Mangano RM, Tzanis E. A comparison of venlafaxine XR and paroxetine in the treatment of outpatients with panic disorder. Neuropsychopharmacology. 2004;29:5201.
127. Pollack MH, Worthington JJ3, Otto MW et al. Venlafaxine for panic disorder: results from a double-blind, placebo-controlled study. Psychopharmacol Bull. 1996;32:667-670.
128. Lydiard RB, Lesser IM, Ballenger JC, Rubin RT, Laraia M, DuPont R. A fixed-dose study of alprazolam 2 mg, alprazolam 6 mg, and placebo in panic disorder. J Clin Psychopharmacol. 1992;12:96-103.
129. Noyes R, Jr., Burrows GD, Reich JH, et al. Diazepam versus alprazolam for the treatment of panic disorder. J Clin Psychiatry. 1996;57:349-355.
130. Schweizer E, Patterson W, Rickels K, Rosenthal M. Double-blind, placebo-controlled study of a once-a-day, sustained-release preparation of alprazolam for the treatment of panic disorder. Am J Psychiatry. 1993;150:1210-1215.
131. Tesar GE, Rosenbaum JF, Pollack MH, et al. Double-blind, placebo-controlled comparison of donazepam and alprazolam for panic disorder. J Clin Psychiatry. 1991;52:69-76.
132. Schweizer E, Rickels K, Weiss S, Zavodnick S. Maintenance drug treatment of panic disorder. I. Results of a prospective, placebo-controlled comparison of alprazolam and imipramine. Arch Gen Psychiatry. 1993;50:51-60.
133. Roy-Byrne P, Wingerson DK, Radant A, Greenblatt DJ, Cowley DS. Reduced benzodiazepine sensitivity in patients with panic disorder: comparison with patients with obsessive-compulsive disorder and normal subjects. Am J Psychiatry. 1996;153:1444-1449.
134. Roy-Byrne PP, Lewis N, Villacres E, et al. Preliminary evidence of benzodiazepine subsensitivity in panic disorder. Biol Psychiatry. 1989;26:744-748.
135. Nutt DJ, Glue P, Lawson C, Wilson S. Flumazenil provocation of panic attacks. Evidence for altered benzodiazepine receptor sensitivity in panic disorder. Arch Gen Psychiatry. 1990;47:917-925.
136. Woods SW, Charney DS, Silver JM, Krystal JH, Heninger GR. Behavioral, biochemical, and cardiovascular responses to the benzodiazepine receptor antagonist flumazenil in panic disorder. Psychiatry Res. 1991;36:115-127.
137. Goddard AW, Mason GF, Almai A, et al. Reductions in occipital cortex GABA levels in panic disorder detected with 1h-magnecic resonance spectroscopy. Arch Gen Psychiatry. 2001;58:556-561.
138. Goddard AW, Mason GF, Appel M, et al. Impaired GABA neuronal response to acute benzodiazepine administration in panic disorder. Am J Psychiatry. 2004;161:2186-2193.
139. Malizia AL, Cunningham VJ, Bell CJ, Liddle PF, Jones T, Nutt DJ. Decreased brain GABA(A)-benzodiazepine receptor binding in panic disorder: preliminary results from a quantitative PET study. Arch Gen Psychiatry. 1998;55:715-720.
140. Kaschka W, Feistel H, Ebert D. Reduced benzodiazepine receptor binding in panic disorders measured by iomazenil SPECT. J Psychiatr Res. 1995;29:427-434.
141. Schlegel S, Steinen H, Bockisch A, Hahn K, Schloesser R, Benkert O. Decreased benzodiazepine receptor binding in panic disorder measured by IOMAZENIL-SPECT. A preliminary report. Eur Arch Psychiatry Clin Neurosci. 1994;244:49-51.
142. Abadie P, Boulenger JP, Benali K, Barre L, Zarifian E, Baron JC. Relationships between trait and state anxiety and the central benzodiazepine receptor: a PET study. Eur Neurosci. 1999;11:1470-1478.
143. Jerabek I, Boulenger JP, Bradwejn J, Lavallee YJ, Jolicoeur B. CCK4-induced panic in healthy subjects I: psychological and cardiovascular effects. Eur Neuropsychopharmacol 1999;9:149-155.
144. Bradwejn J, Koszycki D, Shriqui C. Enhanced sensitivity to cholecystokinin tetrapeptide in panic disorder. Clinical and behavioral findings. Arch Gen Psychiatry. 1991;48:603-610.
145. Strohle A, Holsboer F, Rupprecht R. Increased ACTH concentrations associated with cholecystokinin tetrapeptide-induced panic attacks in patients with panic disorder. Neuropsychopharmacology. 2000;22:251-256.
146. Lydiard RB, Ballenger JC, Laraia MT, Fossey MD, Beinfeld MC. CSF cholecystokinin concentrations in patients with panic disorder and in normal comparison subjects. Am J Psychiatry. 1992;149:691-693.
147. Goldstein S, Halbreich U, Asnis G, Endicott J, Alvir J. The hypothalamic-pituitary-adrenal system in panic disorder. Am J Psychiatry. 1987;144:1320-1323.
148. Holsboer F, von Bardeleben U, Buller R, Heuser I, Steiger A. Stimulation response to corticotropin-releasing hormone (CRH) in patients with depression, alcoholism and panic disorder. Horm Metab Res Suppl. 1987;16:80-88.
149. Wilkinson DJ, Thompson JM, Lambert GW, et al. Sympathetic activity in patients with panic disorder at rest, under laboratory mental stress, and during panic attacks. Arch Gen Psychiatry. 1998;55:511-520.
150. Kathol RG, Noyes R, Jr., Lopez AL, Reich JH. Relationship of urinary free cortisol levels in patients with panic disorder to symptoms of depression and agoraphobia. Psychiatry Res. 1988;24:211-221.
151. Coryell W, Noyes R. HPA axis disturbance and treatment outcome in panic disorder. Biol Psychiatry. 1988;24:762-766.
152. Rapaport MH, Risch SC, Golshan S, Gillin JC. Neuroendocrine effects of ovine corticotropin-releasing hormone in panic disorder patients. Biol Psychiatry. 1989;26:344-348.
153. Roy-Byrne PP, Uhde TW, Post RM, Gallucci W, Chrousos GP, Gold PW. The corticotropin-releasing hormone stimulation test in patients with panic disorder. Am J Psychiatry. 1986;143:896-899.
154. Coplan JD, Pine D, Papp L et al. Uncoupling of the noradrenergic- hypothalamic-pituitary-adrenal axis in panic disorder patients. Neuropsychopharmacology. 1995;13:65-73.
155. Kendler KS, Walters EE, Neale MC, et al. The structure of the genetic and environmental risk factors for six major psychiatric disorders in women. Phobia, generalized anxiety disorder, panic disorder, bulimia, major depression, and alcoholism. Arch Gen Psychiatry. 1995;52:374-383.
156. Stein DJ. Panic disorder. The Cognitive-Affective Neuroscience of Depression and Anxiety Disorders. London, UK: Martin Dunitz Ltd; 2003:57-69.
157. Papp LA, Martinet JM, Klein DF, et al. Respiratory psychophysiology of panic disorder: three respiratory challenges in 98 subjects. Am J Psychiatry. 1997;154:1557-1565.
158. Kent JM, Papp LA, Martinez JM, et al. Specificity of panic response to CO(2) inhalation in panic disorder: a comparison with major depression and premenstrual dysphoric disorder. Am J Psychiatry. 2001;158:58-67.
159. Battaglia M, Ogliari A. Anxiety and panic: from human studies to animal research and back. Neurosci Biobehav Rev. 2005;29:169-179.
160. Sinha S, Papp LA, Gorman JM. How study of respiratory physiology aided our understanding of abnormal brain function in panic disorder. J Affect Disord. 2000;61:191-200.
161. Briggs AC, Stretch DD, Brandon S. Subtyping of panic disorder by symptom profile. Br J Psychiatry. 1993;163:201-209.
162. Nardi AE, Nascimento I, Valenca AM, et al. Respiratory panic disorder subtype: acute and long-term response to nortriptyline, a noradrenergic tricyclic antidepressant. Psychiatry Res. 2003;120:283-293.
163. Valenca AM, Nardi AE, Mezzasalma MA, et al. Therapeutic response to benzodiazepine in panic disorder subtypes. Sao Paulo Med J. 2003;121:77-80.
164. Bertani A, Perna G, Arancio C, Caldirola D, Bellodi L. Pharmacologic effect of imipramine, paroxetine, and sertraline on 35% carbon dioxide hypersensitivity in panic patients: a double-blind, random, placebo-controlled study. J Clin Psychopharmacol. 1997;17:97-101.
165. Gorman JM, Browne ST, Papp LA, et al. Effect of antipanic treatment on response to carbon dioxide. Biol Psychiatry. 1997;42:982-991.
166. Perna G, Bertani A, Caldirola D, Gabriele A, Cocchi S, Bellodi L. Antipanic drug modulation of 35% CO2 hyperreactivity and short-term treatment outcome. J Clin Psychopharmacol. 2002;22:300-308.
167. Bertani A, Caldirola D, Bussi R, Bellodi L, Perna G. The 35% CO2 hyperreactivity and clinical symptomatology in patients with panic disorder after 1 week of treatment with citalopram: an open study. J Clin Psychopharmacol. 2001;21:262-267.
168. Bocola V, Trecco MD, Fabbrini G, Paladini C, Sollecito A, Martucci N. Antipanic effect of fluoxetine measured by CO2 challenge test. Biol Psychiatry. 1998;43:612-615.
169. Schruers K, Griez E. The effects of tianeptine or paroxetine on 35% CO2 provoked panic in panic disorder. J Psychopharmacol 2004;18:553-558.
170. Perna G, Bertani A, Caldirola D, Di Pasquale D, Migliarese G, Bellodi L. Modulation of hyperreactivity to 35% CO2 after one week of treatment with paroxetine and reboxetine: a double-blind, randomized study. J Clin Psychopharmacol 2004;24:277-282.
171. Bertani A, Bellodi L, Bussi R, Caldirola D, Cucchi M, Perna G. The effect of one-week treatment with venlafaxine on 35% CO2 hyperreactivity in patients with panic disorder: an open study. J Clin Psychopharmacol. 2003;23:106-108.
172. Gorman JM, Martinez J, Coplan JD, Kent J, Kleber M. The effect of successful treatment on the emotional and physiological response to carbon dioxide inhalation in patients with panic disorder. Biol Psychiatry. 2004;56:862-867.
173. Gorman JM, Papp LA, Coplan JD, et al. Anxiogenic effects of CO2 and hyperventilation in patients with panic disorder. Am J Psychiatry. 1994;151:547-553.
174. Goetz RR, Klein DF, Papp LA, Martinez JM, Gorman JM. Acute panic inventory symptoms during CO(2) inhalation and room-air hyperventilation among panic disorder patients and normal controls. Depress Anxiety. 2001;14:123-136.
175. Nardi AE, Valenca AM, Nascimento I, Mezzasalma MA, Zin W. Panic disorder and hyperventilation. Arq Neuropsiquiatr. 1999;57:932-936.
176. Nardi AE, Valenca AM, Nascimento I, Mezzasalma MA, Zin WA. Hyperventilation in panic disorder and social phobia. Psychopathology. 2001;34:123-127.
177. Nardi AE, Valenca AM, Nascimento I, Zin WA. Panic disorder and obsessive compulsive disorder in a hyperventilation challenge test. J Affect Disord. 2002;68:335-340.
178. Nardi AE, Valenca AM, Nascimento I, Zin WA. Hyperventilation challenge test in panic disorder and depression with panic attacks. Psychiatry Res. 2001;105:57-65.
179. Krystal JH, Deutsch DN, Charney DS. The biological basis of panic disorder. J Clin Psychiatry. 1996;57(Suppl 10):23-31.
180. Liebowitz MR, Fyer AJ, Gorman JM, et al. Lactate provocation of panic attacks. I. Clinical and behavioral findings. Arch Gen Psychiatry. 1984;41:764-770.
181. Lingjaerde O. Lactate-induced panic attacks: possible involvement of serotonin reuptake stimulation. Acta Psychiatry Scand. 1985;72:206-208.
182. Nutt D, Lawson C. Panic attacks. A neurochemical overview of models and mechanisms. Br J Psychiatry. 1992;160:165-178.
183. Norman TR, Sartor DM, Judd FK, et al. Platelet serotonin uptake and 3H-imipramine binding in panic disorder. J Affect Disord. 1989;17:77-81.
184. Cowley DS, Dunner DL. Response to sodium lactate in panic disorder: relationship to presenting clinical variables. Psychiatry Res. 1988;25:253-259.
185. Knott VJ, Lapierre YD. Neuropsychophysiological correlates of lactate-induced panic. Prog Neuropsychopharmacol Biol Psychiatry. 1988;12:183-192.
186. Yeragani V, Balon R, Pohl R. Lactate infusions in panic disorder patients and normal controls: autonomic measures and subjective anxiety. Acta Psychiatr Scand 1989;79:32-40.
187. Yeragani VK, Pohl R, Balon R, Weinberg P, Berchou R, Rainey JM. Preinfusion anxiety predicts lactate-induced panic attacks in normal controls. Psychosom Med. 1987;49:383-389.
188. Cowley DS, Dager SR, Roy-Byrne PP, Avery DH, Dunner DL. Lactate vulnerability after alprazolam versus placebo treatment of panic disorder. Biol Psychiatry. 1991;30:49-56.
189. Liebowiti MR, Coplan JD, Martinez J, et al. Effects of intravenous diazepam pretreatment on lactate-induced panic. Psychiatry Res. 1995;58:127-138.
190. Pohl R, Balon R, Berchou R, Lycaki H. Lactate-induced anxiety after imipramine and diazepam treatment. Anxiety. 1994;1:54-63.
191. Yeragani VK, Pohl R, Balon R, Rainey JM, Berchou R, Ortiz A. Sodium lactate infusions after treatment with tricyclic antidepressants: behavioral and physiological findings. Biol Psychiatry. 1988;24:767-774.
192. Keck PE, Jr., Taylor VE, Tugrul KC, McElroy SL, Bennett JA. Valproate treatment of panic disorder and lactate-induced panic attacks. Biol Psychiatry. 1993;33:542-546.
193. Shear MK, Fyer AJ, Ball O, et al. Vulnerability to sodium lactate in panic disorder patients given cognitive-behavioral therapy. Am J Psychiatry. 1991;148:795-797.
194. de Montigny C. Cholecystokinin tetrapeptide induces panic-like attacks in healthy volunteers. Preliminary findings. Arch Gen Psychiatry. 1989;46:511-517.
195. Goddard AW, Charney DS. Toward an integrated neurobiology of panic disorder. J Clin Psychiatry. 1997;58(Suppl 2):4-11.
196. Zwanzger P, Eser D, Aicher S, et al. Effects of alprazolam on cholecystokinin-tetrapeptide-induced panic and hypothalamic-pituitary-adrenal- axis activity: a placebo-controlled study. Neuropsychopharmacology. 2003;28:979-984.
197. Zwanzger P, Eser D, Padberg F, et al. Effects of tiagabine on cholecystokinin-tetrapeptide (CCK-4)-induced anxiety in healthy volunteers. Depress Anxiety. 2003;18:140-143.
198. Zwanzger P, Baghai TC, Schuele C, et al. Vigabattin decreases cholecystokinin-tetrapeptide (CCK-4) induced panic in healthy volunteers. Neuropsychopharmacology. 2001;25:699-703.
199. Bradwejn J, Kosrycki D. Imipramine antagonism of the panicogenic effects of cholecystokinin tetrapeptide in panic disorder patients. Am J Psychiatry. 1994;151:261-263.
200. Shlik J, Aluoja A, Vasar V, Vasar E, Podar T, Bradwejn J. Effects of citalopram treatment on behavioural, cardiovascular and neuroendocrine response to cholecystokinin tetrapeptide challenge in patients with panic disorder. J Psychiatry Neurosci. 1997;22:332-340.
201. van Megen HJ, Westenberg HG, den Boer JA, Slaap B, Scheepmakers A. Effect of the selective serotonin reuptake inhibitor fluvoxamine on CCK-4 induced panic attacks. Psychopharmacology (Berl). 1997;129:357-364.
202. Strohle A, Kellner M, Holsboer F, Wiedemann K. Anxiolytic activity of atrial natriuretic peptide in patients with panic disorder. Am J Psychiatry. 2001;158:1514-1516.
203. Wiedemann K, Jahn H, Yassouridis A, Kellner M. Anxiolyticlike effects of atrial natriuretic peptide on cholecystokinin tetrapeptide-induced panic attacks: preliminary findings. Arch Gen Psychiatry. 2001;58:371-377.
204. Bradwejn J, Koszycki D, Couetoux du TA, van Megen H, den Boer J, Westenberg H. The panicogenic effects of cholecystokinin-tetrapeptide are antagonized by L-365,260, a central cholecystokinin receptor antagonist, in patients with panic disorder. Arch Gen Psychiatry. 1994;51:486-493.
205. Kramer MS, Cutler NR, Ballenger JC et al. A placebo-controlled trial of L-365,260, a CCKB antagonist, in panic disorder. Biol Psychiatry. 1995;37:462-466.
206. Sramek JJ, Kramer MS, Reines SA, Cutler NR. Pilot study of a CCKB antagonist in patients with panic disorder preliminary findings. Anxiety. 1994;1:141-143.
207. Hosing VG, Schirmacher A, Kuhlenbaumer G, et al. Cholecystokinin- and cholecystokinin-B-receptor gene polymorphisms in panic disorder. J Neural Transm Suppl. 2004;147-156.
208. Miyasaka K, Yoshida Y, Matsushita S, et al. Association of cholecystokinin-A receptor gene polymorphisms and panic disorder in Japanese. Am J Med Genet B Neuropsychiatr Genet. 2004;127:78-80.
209. Ise K, Akiyoshi J, Horinouchi Y, Tsutsumi T, Isogawa K, Nagayama H. Association between the CCK-A receptor gene and panic disorder. Am J Med Genet B Neuropsychiatr Genet. 2003;118:29-31.
210. Hamilton SP, Slager SL, Helleby L, et al. No association or linkage between polymorphisms in the genes encoding cholecystokinin and the cholecystokinin B receptor and panic disorder. Mol Psychiatry. 2001;6:59-65.
211. Kennedy JL, Bradwejn J, Koszycki D, et al. Investigation of cholecystokinin system genes in panic disorder. Mol Psychiatry. 1999;4:284-285.
212. Charney DS, Woods SW, Goodman WK, Heninger GR. Neurobiological mechanisms of panic anxiety: biochemical and behavioral correlates of yohimbine-induced panic attach. Am J Psychiatry. 1987;144:1030-1036.
213. Gurguis GN, Uhde TW. Plasma 3-methoxy-4-hydroxyphenylethylene glycol (MHPG) and growth hormone responses to yohimbine in panic disorder patients and normal controls. Psychoneuroendocrinology. 1990;15:217-224.
214. Gurguis GN, Vitton BJ, Uhde TW. Behavioral, sympathetic and adrenocortical responses to yohimbine in panic disorder patients and normal controls. Psychiatry Res. 1997;71:27-39.
215. Yeragani W, Berger R, Pohl R, et al. Effects of yohimbine on heart rate variability in panic disorder patients and normal controls: a study of power spectral analysis of heart rate. J Cardiovasc Pharmacol. 1992;20:609-618.
216. Charney DS, Heninger GR. Noradrenergic function and the mechanism of action of antianxiety treatment. I. The effect of long-term alprazolam treatment. Arch Gen Psychiatry. 1985;42:458-467.
217. Charney DS, Heninger GR. Noradrenergic function and the mechanism of action of antianxiety treatment. II. The effect of long-term imipramine treatment. Arch Gen Psychiatry. 1985;42:473-481.
218. Goddard AW, Woods SW, Sholomskas DE, et al. Effects of the serotonin reuptake inhibitor fluvoxamine on yohimbine-induced anxiety in panic disorder. Psychiatry Res. 1993;48:119-133.
219. Gurguis GN, Antai-Otong D, Vo SP, et al. Adrenergic receptor function in panic disorder. I. Platelet alpha 2 receptors: Gi protein coupling, effects of imipramine, and relationship to treatment outcome. Neuropsychopharmacology. 1999;20:162-176.
220. Yeragani VK, Srinivasan K, Pohl R, Berger R, Balon R, Ramesh C. Effects of nortriptyline on heart rate variability in panic disorder patients: a preliminary study using power spectral analysis of heart rate. Neuropsychobiology. 1994;29:1-7.
221. Charney DS, Heninger GR, Jatlow PI. Increased anxiogenic effects of caffeine in panic disorders. Arch Gen Psychiatry. 1985;42:233-243.
222. Boulenger JP, Uhde TW, Wolff EA III, Post RM. Increased sensitivity to caffeine in patients with panic disorders. Preliminary evidence. Arch Gen Psychiatry. 1984;41:1067-1071.
223. Lam P, Hong CJ, Tsai SJ. Association study of A2a adenosine receptor genetic polymorphism in panic disorder. Neurosci Lett. 2005;378:98-101.
224. 2A receptor gene polymorphisms and caffeine-induced anxiety. Neuropsychopharmacology. 2003;28:1694-1702.
225. van West D, Claes S. The genteics of panic disorder: state of the art. Acta Neuropsychiatrica. 2004;16:68-78.
226. van den Heuvel OA, van de Wetering BJ, Veltman DJ, Pauls DL. Genetic studies of panic disorder: a review. J Clin Psychiatry. 2000;61:756-766.
227. Merikangas KR, Pine D. Genetic and other vulnerability factors for anxiety and stress disorders. In: Davis KL, Charney D, Coyle JT, Nemeroff C, eds. Neuropsychopharmacology: The Fifth Generation of Progress. 2002:867-882.
228. Schwartz CE, Wright CI, Shin LM, Kagan J, Rauch SL. Inhibited and uninhibited infants "grown up": adult amygdalar response to novelty. Science. 2003;300:1952-1953.
229. Hariri AR, Weinberger DR. Functional neuroimaging of genetic variation in serotonergic neurotransmission. Genes Brain Behav. 2003;2:341-349.